AbbVie’s Gaps Are Neurocrine’s Gains

Neurocrine’s women’s health candidate, which it out-licensed to Abbott in 2010, is starting to gather steam. The candidate is benefitting from favorable data and a pressing need by Abbott spin-out, AbbVie, to succeed with its late-stage pipeline.